Abstract Drug pharmacokinetics (PK) is influenced by multiple intrinsic and extrinsic factors, among which concomitant medications are responsible for drug-drug interactions (DDIs) that may have a clinical relevance, resulting in adverse drug reactions or reduced efficacy. The addition of intrinsic factors affecting cytochromes P450 (CYPs) activity and/or expression, such as genetic polymorphisms and diseases, may potentiate the impact and clinical relevance of DDIs. In addition, greater variability in drug levels and exposures has been observed when such intrinsic factors are present in addition to concomitant medications perpetrating DDIs. This variability results in poor predictability of DDIs and potentially dramatic clinical consequences. The present review illustrates the issue of complex DDIs using systematically searched published case reports of DDIs involving genetic polymorphisms, renal impairment, cirrhosis, and/or inflammation. Current knowledge on the impact of each of these factors on drug exposure and DDIs is summarized and future perspectives for the management of such complex DDIs in clinical practice are discussed, including the use of advanced Computerized Physician Order Entry (CPOE) systems, the development of model-based dose optimization strategies, and the education of healthcare professionals with respect to personalized medicine.
Further scientific research is needed to integrate intrinsic factors in the prediction of DDIs, together with the development of advanced integrated e-patient medical dossiers and education of healthcare professionals with respect to personalized medicine.
Introduction
With the increase of life expectancy and population aging, patients tend to have multiple chronic diseases, such as diabetes, hypertension, hypercholesterolemia, and depression. Polymorbidity in elderly patients often involves the prescription of several concomitant drug treatments, increasing the risk of potentially harmful drug-drug interactions (DDIs), which are a major cause of adverse drug reactions (ADRs), frequently leading to hospitalization [1] [2] [3] [4] . Indeed, the risk of DDIs increases with the number of concomitant prescriptions: from 13% with two concomitant drugs, to 38% with four concomitant durgs and 82% with eight or more concomitant drugs [5] . To note, it was reported that the frequency of elderly patients taking eight or more concomitant medications was [ 10% [6] . The nature of DDIs can be pharmacokinetic (PK, affecting the disposition of the drug) and/or pharmacodynamic (PD, affecting the effect of the drug without affecting its concentration). Regarding the latter, a drug can affect the absorption, distribution, metabolism and elimination of another drug. Of particular interest, cytochromes P450 (CYPs) are involved in the metabolism of a large number of drugs, in particular those belonging to families 1, 2 and 3. Their importance in clinical practice and drug development lies in the large interindividual variability of both their expression and activity, which might be explained by intrinsic factors (age, disease, sex, weight, and genetics) and/or extrinsic factors (xenobiotics).
In the last decades, CYP-related DDIs have been extensively studied. Currently, clinically relevant DDIs can be detected by both the prescribers and the delivering pharmacists through interaction alert software such as Lexi-Interact [7] , ePocrates [8] , and Theriaque [9] , thus allowing for the identification, management and prevention of DDI-related ADRs and therapeutic inefficiency. Because the association of two interacting drugs cannot always be avoided, increasing efforts have been provided to develop a mechanistic model to quantitatively predict DDIs, allowing for prospective dose adjustment [10] . Such models include basic static, mechanistic static, and dynamic physiologically-based PK (PBPK) models. However, complex DDI scenarios are becoming increasingly frequent, partly because our scientific knowledge is constantly developing and partly because of patients' increasingly complex clinical features (aging and polymorbidity) and treatments, and still remain difficult to predict. These complex DDI scenarios may include drug-related complexities such as simultaneous involvement of multiple enzymes and transporters, simultaneous inhibition and induction, mechanisms of autoinhibition/induction, time-dependent inhibition, inhibition/induction caused by major metabolites, association of multiple perpetrators, and patient-related complexities such as involvement of genetic variants and diseases affecting drug disposition.
Interaction trials are often performed on early-stage clinical development with healthy volunteers or preselected patients. Nevertheless, genetic variants of CYP isoforms of clinical interest are not rare and 'real life' patients often have comorbidities that may affect drug disposition, such as renal failure, liver dysfunction, or inflammation. While each individual factor may not have a major impact on the PK and PD of drugs, the consequence of their combined effect might be clinically significant and deleterious.
This review aims to focus on DDIs involving patientrelated complexities, namely genetic polymorphisms and diseases affecting drug disposition from a clinical perspective. First, published case reports of DDIs complicated by genetic variants, renal failure, cirrhosis, or inflammation are described, and the effect of genetic polymorphisms and diseases on drug disposition and their implication on DDIs are then discussed. Finally, clinical perspectives regarding the management of such complex DDI scenarios are presented.
Case Reports Review

Methods
Case reports involving CYP-related DDIs and genetic polymorphisms, cirrhosis, renal failure, or inflammation were searched using the PubMed database and reviewed systematically. The PubMed database search algorithm is described in the electronic supplementary material and contains terms related to CYPs (families 1, 2 and 3), drug interactions, and case reports. Language was restricted to English and French, but there were no restrictions on the year of publication. Search results were first screened based on title and abstract in order to rule out off-topic publications, and full-texts of selected publications were then reviewed in order to verify if they fulfilled all the following eligibility criteria: coherent PK interaction involving CYP, information on CYP genotype, renal function, cirrhotic status, or inflammatory state. Renal function and inflammatory state had to be assessed by biomarkers, such as serum creatinine/glomerular filtration rate (GFR) and C-reactive protein (CRP)/interleukin (IL)-6/white blood cell count, respectively.
Results
The systematic search workflow is presented in Fig. 1 . Overall, 877 records were output from the PubMed search performed on 13 July 2017. Of these, 769 were excluded based on the title and abstract because they were off-topic. Of the 108 selected records, 46 were excluded because they did not fulfill the eligibility criteria described in the Methods section.
Eligible publications were dated from 1998 to 2017. Among the 62 eligible publications, only one was in French, while all others were in English. Language restrictions were not considered to have a deleterious effect on the quality of the present review, with its aim being illustrative rather than quantitative. Moreover, it has not been proven that language restriction has any notable impact on the results of meta-analyses [11] .
The 62 eligible publications presented 34 cases of drugdrug-gene interactions (DDGIs), 25 cases of drug-drugdisease interactions (DDDIs), and 4 cases of drug-druggene-disease interactions (DDGDIs), which are summarized in Tables 1, 2 and 3, respectively. DDIs found in the selected literature included 33 victim drugs and 44 perpetrator drugs. The most cited CYP substrates were simvastatin, tacrolimus, colchicine and voriconazole, while the most cited CYP perpetrators were the inhibitors clarithromycin, ritonavir, and diltiazem (see Tables 4 and 5 for a complete list of victim and perpetrator drugs). There were only a few induction-related DDIs, which were perpetrated by the CYP inducers carbamazapine and rifampin.
The mechanisms of these complex DDIs are numerous: (1) enhancement of the magnitude of interaction due to a genetic variant directly impacting the CYP isoform of interest [12, 13] ; (2) increased vulnerability to phenoconversion (i.e. the phenomenon that occurs when a perpetrator drug of DDIs is strong enough to modify the phenotype of an individual [14, 15] ) caused by a genetic variant or disease directly affecting the inhibited/induced metabolic pathway ; (3) increased exposure of the perpetrator drug due to genetic polymorphisms [21, 25, 26, 60, [63] [64] [65] [66] [67] [68] ; and (4) modification of the relative contribution of a minor pathway by a genetic variant or Fig. 1 Systematic search in accordance with the PRISMA workflow. PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses, DDGI drug-drug-gene interaction, DDDI drug-drugdisease interaction, DDGDI drug-drug-gene-disease interaction Complex Drug-Drug-Gene-Disease Interactions Complex Drug-Drug-Gene-Disease Interactions If the dosage is not specified, the data could not be found in the case report. If not specified, the administration route is orally Complex Drug-Drug-Gene-Disease Interactions bpm beats per minute, C clinical outcome, C 8h concentration every 8 h, C 0 trough concentration, CRP C-reactive protein, C ss concentration at steady state, CYP cytochrome P450, eGFR estimated glomerular filtration rate, F female, IV intravenous, M male, PD pharmacodynamic outcome, PK pharmacokinetic outcome, PO orally, RI renal insufficiency, WBC white blood cells, : indicates increase, ; indicates decrease a If the dosage is not specified, the data could not be found in the case report. If not specified, the administration route is orally disease affecting another major pathway [58, 60, 61, [69] [70] [71] [72] [73] [74] [75] .
Interestingly, complex DDIs were perpetrated by drugs with CYP-inhibiting/inducing potencies ranging from weak to strong. In some cases, drugs described as having null to negligible effects on CYP activity at therapeutic doses, such as colchicine, felodipine, pantoprazole, propanolol, tacrolimus, azithromycin (CYP3A), amitriptyline, metoprolol (CYP2D6), haloperidol (CYP3A), and aripiprazole (CYP2D6, CYP3A) might have been capable of inhibiting ARV antiretrovirals, C clinical outcome, CRP C-reactive protein, F female, M male, PK pharmacokinetic outcome, RI renal insufficiency, UM ultrarapid metabolizer, : indicates increase a If the dosage is not specified, the data could not be found in the case report. If not specified, the administration route is orally
Complex Drug-Drug-Gene-Disease InteractionsCYP pathways due to either increased vulnerability to phenoconversion caused by genetic or disease particularities, or enhanced exposure related to genetic polymorphisms. Victim drugs were affected by CYP inhibitors and inducers either through major or minor metabolic pathways. In the latter case, inhibition of a major metabolic pathway by a genetic variant or disease allowed boosting of the minor pathway relative contribution to overall drug metabolism (f m ). The f m value has a high impact on the magnitude of DDIs. When a major elimination pathway is inhibited, the contribution of the minor pathway is enhanced; therefore, the magnitude of DDIs can be dramatically increased when multiple elimination pathways are inhibited. Whereas the effect of inhibition of the minor pathway would not be significant in most individuals, it might become clinically relevant when the major pathway is non-functional.
Genetic Polymorphisms
CYPs are subject to genetic polymorphisms, defined as stable variations in a given locus of the genetic sequence, which are detected in 1% or more of a specific population [129] . Among these CYPs, the most polymorphic genes are CYP2C9, CYP2C19 and CYP2D6; however, genetic variants of other enzymes, such as CYP1A2, CYP3A4, CYP3A5, and CYP2B6, have also been described. Variant alleles of CYP-coding genes may either lead to CYP cytochrome P450 [128] significantly decreased or increased enzyme activity, or regulated gene expression leading to lack of or overexpression of coded enzymes [130] . The impact of CYP genetic variants on the PK of substrate drugs (such as CYP2C9 for vitamin K antagonists, CYP2C19 for clopidogrel, and CYP2D6 for opioid analgesics, tamoxifen, and antidepressants) have been extensively studied in the last decades. Genetic-based dosing guidelines constitute a useful tool for the management of gene-drug interactions (GDIs) in clinical practice. When a GDI cannot be avoided through modification of therapeutic entity, dose adjustment or safety/efficacy monitoring might be proposed to manage such interactions and avoid therapeutic failure and/or ADRs. The clinical relevance of preemptive genotyping is supported by recent studies that estimate the proportion of the population carrying at least one actionable pharmacogenetic variant to be over 90% [131] [132] [133] . The clinical benefit of pre-emptive genotyping of the major genes involved in the PK and PD of drugs is currently assessed in several prospective implementation studies [134] [135] [136] [137] [138] [139] . A recent study by an American genetic testing laboratory with more than 22,000 patients reported that among all patients with at least one drug interaction in their medication list (69% of the cohort), 53% were DDIs, 25% were GDIs, and 22% were DDGIs [140] .
The simultaneous presence of both GDIs and DDIs may be responsible for greater clinical relevance (efficacy/ safety) of such interactions, as reported in the case reports described herein. In addition, the complexity of the latter type of drug interactions results in greater variability in drug levels and difficulty of DDI predictions. The impact of genetic polymorphisms on CYP-mediated DDIs has been highlighted in several studies in the past years. Bahar and colleagues recently published a comprehensive systematic review on DDGIs involving the most polymorphic enzymes (CYP2C9, CYP2C19 and CYP2D6) that summarized the available clinical studies on this topic [141] . The present review adds clinical illustrations of such drug interactions.
Among the DDGI cases described in the present study, some had severe or fatal outcomes. In a psychotic 50-yearold patient with inactive CYP2D6 (CYP2D6*4/*5), the addition of carbamazepine to a stable risperidone regimen resulted in a significant decrease of active moiety levels, leading to an exacerbation of psychotic symptoms [70] . Severe psychosis related to toxic levels of efavirenz resulted from the coadministration of efavirenz, ritonavir and fluconazole in a 33-year old HIV-positive woman carrying the CYP2B6 516TT genetic variant. In this case, the inhibition of CYP3A by fluconazole, which normally has a modest effect on efavirenz exposure, became significant because of the altered CYP2B6 major pathway [71] . A case of a DDGI explained by both increased vulnerability to phenoconversion and increased exposure of the perpetrator was well-described in a 17-year-old transplant recipient, with overtherapeutic tacrolimus levels becoming even higher and resulting in acute nephrotoxicity after omeprazole initiation despite a dose reduction of the immunosuppressant [26] . Genotyping revealed that the patient was a non-expressor of CYP3A5, the major enzyme involved in tacrolimus metabolism. In addition, the patient was a poor metabolizer (PM) of CYP2C19 (CYP2C19*2/ *2) and carried non-functional variants of ABCB1 coding for P-glycoprotein (P-gp). In this case, omeprazole likely inhibited tacrolimus elimination through competition with the CYP3A4 pathway (minor metabolic pathway of omeprazole) due to genetic polymorphisms of both CYP2C19 (major pathway of omeprazole elimination) and CYP3A5 (preferred metabolic pathway of tacrolimus). As a last example of dramatic outcomes of DDGIs, lethal levels of hydrocodone were found in a 5-year-old child who received twice the recommended dose of hydrocodone (30 mg over 24 h). In this case, the fatal outcome was a consequence of overdose, reduced CYP2D6 activity (CYP2D6 genotype *2A/*41), and concomitant administration of CYP3A inhibitors (clarithromycin and valproic acid) [20] .
Two scenarios can be considered when assessing the impact of DDGIs: (1) introduction of a perpetrator drug in a patient stabilized with a victim drug; and (2) addition of a victim drug in a patient treated by a perpetrator. In the first case, one may consider the magnitude of DDIs relative to genotype, while, in the second case, the point of view may focus on genotype-related vulnerability to phenoconversion and on the superposition of mechanisms of both DDIs and GDIs.
In the first case, the dose of the victim drug is probably already modified according to the genetic variant before introduction of the perpetrator, and the magnitude of the DDI will depend on the genotype-relative contribution of the inhibited/induced CYP pathway. As previously discussed, the impact of the f m value of the inhibited clearance pathway to the extent of DDI is well known and the effect of even slight variations in f m values can be clinically important, especially when the f m value approaches 1 [142] . In the case of CYP inhibition, the higher the contribution of the enzymatic pathway, the higher the magnitude of DDIs [108, [143] [144] [145] . A PM of a specific CYP isoform will not be greatly affected by an inhibitor of the variant isoform of interest. In healthy CYP2D6 PM Caucasian subjects, no increase in the AUC of metoprolol was observed when coadministered with dronedarone, a moderate CYP2D6 inhibitor [146] . In CYP2D6 PM psychiatric patients, the MR of debrisoquine, a historical phenotyping probe of CYP2D6, remained unchanged when increasing the thioridazine dose [147] . In a clinical study with healthy Japanese subjects, inhibition of aripiprazole metabolism by paroxetine was significantly greater in extensive metabolizers (EMs) than in intermediate metabolizers (IMs). There was no marked difference with fluvoxamine, a less potent inhibitor [143] . In Korean subjects, the frequent CYP2D6*10 allele, which leads to decreased activity of CYP2D6, showed an impact on the extent of CYP inhibition by paroxetine, a strong time-dependent inhibitor [144] . Another study highlighted the differential inhibition extent of haloperidol metabolism by chlorpromazine in Japanese schizophrenic patients in relation to CYP2D6*5 and *10 alleles [108] . The interaction between fluconazole 200-400 mg/day and flurbiprofen was studied in a clinical study with healthy volunteers, which demonstrated that changes in flurbiprofen apparent oral clearance caused by fluconazole coadministration were gene dose-dependent, with only modest change occurring in CYP2C9 PM subjects [148] . When a major metabolic pathway is inhibited by a genetic variant, such as CYP2C9 for warfarin, the contribution of other pathways increases. This has been demonstrated in CYP2C9-genotyped patients treated with warfarin [149] for which the coadministration of simvastatin (a substrate of CYP3A) required an approximately 29% dose reduction in PMs compared with 5% in EMs [149] . In such cases, an inhibitor of the minor pathway that would not have any significant impact in a wild-type patient can cause severe DDIs in patients with a generelated defect of the major clearance pathway.
In the second scenario, where a victim drug is initiated in a patient treated with a perpetrator drug, the impact of the interaction results from the superposition of GDI and DDI mechanisms. In the absence of an inhibitor/inducer, dose adjustment of a CYP substrate with a genetic variant might be performed during treatment initiation. In the case of concomitant administration of a perpetrator of DDIs, dose adjustment is complicated and requires taking into account both GDIs and DDIs. A genetic variant decreasing the activity of a specific CYP isoform will result in increased vulnerability to DDIs. IM subjects are thought to be more vulnerable to phenoconversion than EMs, while ultrarapid metabolizers (UMs) were less vulnerable because of higher basal CYP activity. Indeed, a higher proportion of subjects in an IM population will be converted to PMs (and will therefore not be able to clear substrate drugs of the polymorphic enzyme) than in a UM population, whose basal capacity of drug metabolism is higher. For example, in patients treated for depression by any known inhibitor of CYP2D6, phenoconversion to PM was observed in 24% of patients. After stratification of study subjects by their genotype, it appeared that conversion to the PM phenotype occurred in 21% of genetic EM subjects and in only 3% of genetic UM subjects [150] . In patients taking acenocoumarol, the presence of genetic variants of CYP2C9 increased the risk of overanticoagulation in the presence of CYP2C9 inhibitors, from 52 to 78% [151] . We recently performed a prospective clinical trial that aimed at assessing the risk of phenoconversion in CYP2D6 genetically predicted EMs and found a higher rate of phenoconversion to PMs with paroxetine in heterozygous carriers of a non-functional allele compared with homozygous carriers of two functional alleles [152] . Therefore, the lower the CYP basal activity, the higher the incidence of phenoconversion and levels of drugs with concomitant administration of a CYP inhibitor. This might have clinical consequences when victim drugs have a narrow therapeutic window.
Complexity is even greater if the magnitude of a DDI and its clinical impact is modified when a genetic variant affects the concentrations of a perpetrator. This has been demonstrated with healthy volunteers genotyped for CYP2C19 and receiving concomitant administration of voriconazole and tacrolimus. In this case, genetic defects of CYP2C19 were associated with increased exposure to voriconazole and corresponding interaction with the CYP3A substrate tacrolimus, which was greater in CYP2C19 PMs than EMs [153] . Among the case reports described herein, many were related to the interaction between tacrolimus and proton pump inhibitors (PPIs). Lansoprazole and omeprazole may affect the elimination of tacrolimus through competition for the CYP3A pathway. In the presence of a genetic defect of CYP2C19, the exposure of PPIs increases, which directly affects the magnitude of interaction between the concomitantly administered drugs. This was described in patients carrying homozygous and heterozygous non-functional CYP2C19 alleles, such as *2 and *3 [63, 64, 67, 68] . This interaction may even be worsened by the addition of other genetic variants affecting tacrolimus elimination, such as CYP3A5*3 (no expression of the CYP3A5 enzyme) or loss-of-function mutations of the ABCB1 gene coding for the efflux transporter P-gp.
To sum, complex DDGIs involve several mechanisms: effect on the exposure of the perpetrator, effect on the exposure of the victim drug, and effect on the magnitude of DDIs. These three mechanisms may be concomitant and cause unexpected serious ADRs.
In recent years, there has been growing interest for the prediction of such complex DDGIs. Tod et al. published a mechanistic static approach to predict the magnitude of DDIs involving CYPs and several genotypes. This approach takes into account the contribution of each individual isoenzyme to the clearance of the drug (CR), the impact of genetic variation on the residual CYP activity, and the potency of perpetrator drugs. [154] The DDI simulator 'DDI Predictor', available online at www. ddipredictor.org, is based on this quantitative prediction [155] ; however, this static approach does not take into account the genetic-related changes in perpetrator drug exposure. By defining drug-dependent and system-dependent parameters in a single prediction model, PBPK modeling offers the needed tools to allow for accurate prediction of complex DDGIs. Vieira and colleagues have recently shown that the additive impact of genetic polymorphisms of CYP2D6 on the interaction between risperidone and fluoxetine could be successfully predicted by PBPK modeling [156] .
Renal Failure
Chronic kidney disease (CKD) is an increasing burden worldwide, with a consistent estimated global prevalence of between 11 and 13% [157] . CKD is defined by a decrease in kidney function, shown by a GFR \ 60 mL/ min/1.73 m 2 and/or markers of kidney damage of at least 3 months' duration [158] . The primary pathological features of most CKDs are interstitial fibrosis, tubular atrophy, and glomerulosclerosis, and are mainly caused by everincreasing pathologies such as diabetes and hypertension [158] . Acute kidney injury (AKI) arises from various etiologies such as tubular, glomerular, and vascular damages [159, 160] .
It is well accepted and intuitive that the clearance of drugs whose elimination mainly depends on renal filtration and/or renal transporters is decreased in CKD and AKI. In addition, an increasing number of in vitro [161] [162] [163] [164] [165] and in vivo (in rats [164, 166, 167] and humans [168, 169] ) studies published in the last 15 years revealed that CKD and end-stage renal disease (ESRD) may decrease the nonrenal clearance of drugs eliminated by metabolizing enzymes and transporters. These data have been incorporated in a PBPK model of renal impairment in which CYP abundance was reduced by 15-85% depending on CYP isoform and renal disease severity compared with healthy controls [170] . In a survey by the US FDA, it was reported that for over 23 new drugs for which applications included renal impairment studies, 13 exhibited an increased exposure in patients with renal impairment (50% on average) compared with healthy volunteers. Yeung and colleagues reported 76 drugs that exhibited altered non-renal clearance in patients with CKD [171] , most of which were eliminated by CYP-mediated hepatic metabolism. Based on these data, both the FDA and the European Medicines Agency (EMA) currently recommend performing PK studies of non-renally cleared drugs in ESRD patients [172, 173] . To date, underlying mechanisms of a drug non-renal clearance decrease in CKD patients are unclear but seem to be related to downregulation of CYP gene expression and/or direct inhibition of CYP by the accumulation of uremic toxins (urea, parathyroid hormone, indoxyl sulfate, and inflammatory cytokines) [174] . However, despite accumulating evidence, trends in the impact of renal impairment on CYP abundance and/or CYP intrinsic clearance are not consistent [160] . Physiological changes that occur in kidney diseases may alter the clearance of non-renally eliminated drugs. In particular, hypoalbuminemia and drug displacement by endogenous compounds (e.g. hippuric acid) that accumulate in patients with impaired renal function reduce albumin binding and therefore raise the non-renal clearance of drugs through an increase in the unbound fraction [171] . Thus, a lack of change in total clearance may obscure reduced enzyme activity and/or abundance in case of concomitant change of the unbound fraction. Therefore, further investigations are needed to understand the net effect of renal disease on CYP activity and expression.
Based on these considerations, kidney disease may affect the clinical impact of DDIs by two mechanisms affecting either the exposure of the victim drug or the extent of the DDI: (1) alteration of the elimination of drugs whose clearance partially or mainly depends on renal function; and (2) inhibition of CYP activity induced by the disease. In addition, the extent of the DDI is impacted by exposure of the perpetrator, which may increase in cases of renal dysfunction. Moreover, by affecting both renal and CYP-mediated hepatic clearance, kidney disease alters the relative contributions of CYP enzymes and therefore the magnitude of CYP-related DDIs.
Among the 29 cases of DDDIs, 21 involved renal failure. Simvastatin, whose elimination is mainly cleared by CYP3A with negligible renal participation (\ 0.5% is recovered unchanged in urine), exhibits reduced non-renal clearance in CKD patients [171] . Indeed, patients with severe renal failure (GFR \ 30 mL/min) showed twofold higher plasma concentrations after a single dose compared with healthy volunteers [175] . The present review described six cases of simvastatin toxicity related to DDDIs (rhabdomyolysis, elevation of liver function tests, renal failure). The perpetrators were not only well-known strong CYP3A inhibitors, such as clarithromycin and amiodarone, but also weak inhibitors of CYP3A, such as azithromycin, and drugs metabolized by the CYP3A pathway that might competitively alter the CYP3A-mediated metabolism of simvastatin, such as colchicine, tacrolimus, sirolimus, and telaprevir. In those cases, the association of both kidney disease and DDIs probably resulted in the development of ADRs. Of note, in three of these cases the daily dose of simvastatin was 80 mg, which is associated with a fourand tenfold higher risk of elevation of liver function tests and creatine kinase, respectively, compared with moderate dosing [176] .
Colchicine is predominantly eliminated by biliary excretion and is a substrate of P-gp. CYP3A-mediated hepatic metabolism and renal elimination account only for 5-20 and 10-20%, respectively, of drug disposition in normal conditions [82] ; however, their impact might become critical in cases of DDIs or genetic variants affecting P-gp [82] . The present review describes five cases of colchicine toxicity-four with clarithromycin and one with cyclosporin. The two perpetrators are both CYP3A and P-gp inhibitors. Colchicine toxicity was precipitated by the superposition of three mechanisms: reduction of biliary excretion by inhibition of P-gp, inhibition of CYP3A-mediated metabolism, and alteration of renal elimination related to kidney disease. The disposition of clarithromycin is dependent on renal elimination, and kidney dysfunction may have led to increased exposure of the perpetrator, therefore worsening the DDI.
Overall, renal impairment was found to be a concomitant disease in more than 20 cases of DDIs. The drugs involved in the DDDIs were primarily cleared by non-renal routes. Renal impairment probably acted as a compounding factor of DDIs, leading to clinical toxicity by increasing the victim drug's exposure through inhibition of renal elimination and/or decrease of CYP expression and/or activity. In addition, the magnitude of DDIs may have been worsened by an increase in the inhibitor's exposure.
System-dependent parameters such as enzyme abundance, gastric emptying time, binding proteins in plasma, and hematocrit have been incorporated in renally impaired virtual populations in PBPK software (SimCYP Ò , Certara, Princeton, NJ, USA). Provided that a PBPK model is capable of predicting comparable PK changes observed in vivo by both individual intrinsic (renal impairment) and extrinsic (interacting drugs) factors, it can be used to predict the combined effect of those factors in common complex scenarios. However, this is not always the case, as shown in the simulated interaction between telithromycin and ketoconazole that yielded a predicted AUC ratio lower than that observed in vivo [177] . These limited observations (derived from only two subjects) warrant further development and validation of current PBPK models.
Hepatic Impairment: Cirrhosis
The liver plays a major role in the absorption, distribution, and elimination of many drugs and their active and inactive metabolites. Liver diseases, particularly cirrhosis, result in numerous physiological changes that may influence drug PK [178] . Liver cirrhosis is characterized by the progressive loss of functional hepatocytes, with concomitant formation of connective tissues and nodules [179] . Progression of the disease might be classified using the Child-Pugh score, which defines the severity of the disease (A, B, C) and the estimated prognosis. Cirrhosis results in the reduction of liver blood flow, the presence of portalsystemic shunting, and a reduction in the number and activity of hepatocytes, as well as in impaired production of drug-binding proteins [178] . In addition, renal function might often become impaired in advanced liver disease, often corresponding to hepatorenal syndrome [180] .
For drugs metabolized primarily in the liver, the total clearance of a compound is the hepatic clearance, which is the product of liver blood flow (Q H ) and the hepatic extraction ratio (E H ), the latter being dependent on the unbound fraction of the drug in blood (f u,B ) , the unbound intrinsic clearance (CL u,int ), and the liver blood flow, as illustrated in Eq. 1:
The hepatic clearance of drugs with high extraction ratios (E H [ 0.7) is limited by hepatic blood flow; therefore, the latter has a high impact on the clearance of highly extracted drugs. Oppositely, hepatic clearance of drugs with low extraction ratios (E H \ 0.3) is considered to be limited by the metabolic capacity. Their clearance is therefore impacted by changes in protein binding and intrinsic hepatic clearance, both occurring in liver disease. Finally, drugs with intermediate extraction ratios (0.3 \ E H \ 0.7) can be impacted by alterations of one of the three components of the equation, i.e. liver blood flow, protein binding, and intrinsic hepatic clearance.
As a result of a reduced first-pass effect, the bioavailability of intermediate to highly extracted drugs is significantly increased in cirrhotic patients. In addition, the impaired production of albumin and a-glycoprotein related to liver dysfunction causes an increase in the unbound fraction of drugs. This change particularly affects the PK of highly bound drugs (f u,B \ 0.1), impacting both their distribution (increased volume of distribution) and clearance (only the unbound fraction is cleared by the liver). The intrinsic metabolic capacity is also altered in liver disease. Indeed, it appears that the expression and activity of CYP are selectively reduced in liver disease. The extent of impairment of metabolic activity and enzyme expression depends on CYP isoform, and the type and severity of liver disease [181] . In addition, the impairment of renal function in advanced cirrhosis might explain the impact of cirrhosis in the PK of drugs with predominant renal elimination.
It was postulated that the reduction of hepatic blood flow in cirrhosis may lead to an increased sensitivity of flowlimited clearance drugs with high extraction ratios to the action of enzymatic inhibitors. Indeed, flow-limited drugs might become capacity-limited with reduction of hepatic blood flow [182] ; however, it seems that the magnitude of DDIs decreases as the liver dysfunction progresses. Indeed, the clearance of lidocaine, a flow-dependent drug with a high extraction ratio, was decreased by 60% in healthy volunteers, and by 44 and 9% in Child-Pugh A and C cirrhotic patients, respectively, when coadministered with fluvoxamine, an inhibitor of CYP1A2 and CYP3A [183] . The magnitude of the decrease of theophylline clearance by fluvoxamine was also dependent on liver function, with inhibition of 65, 55 and 14% in healthy volunteers and Child-Pugh A and C cirrhotic patients, respectively [184] . The impact of clearance inhibition of the CYP3A substrate quinine by erythromycin was also decreased in cirrhotic patients but to a lesser extent, probably because of additional mechanism of competition for protein binding with erythromycin that may mask the decrease in hepatic clearance [182] . Therefore, it seems that decreased uptake of the CYP inhibitor in hepatocytes, together with decreased enzyme expression (and thus decreased contribution of the latter to drug clearance) are responsible for the decreased extent of CYP inhibition on liver cirrhosis. The mechanism of inhibition, whether reversible or irreversible, might also play a role in the liver status-dependency of DDIs [184] .
Regarding CYP induction, it was demonstrated in rats that severe liver dysfunction reduces the expression of the aryl hydrocarbon receptor (AhR), and consequently the expression and inducibility of CYP1A enzymes [185] . To our knowledge, no human clinical study was properly designed to assess the impact of liver dysfunction on CYP induction.
Because the impact of liver dysfunction on drug PK and DDIs was mostly described with cirrhosis, only the latter was selected in the present review. Seven cases of DDDIs involved cirrhosis as a concomitant disease. Given previous considerations related to the impact of liver dysfunction on the extent of DDIs, it seems that cirrhosis only represents a compounding factor through elevation of basal circulating levels of the victim drugs and not through an increase of the magnitude of DDIs. While cirrhosis might minimize the magnitude of DDIs, in the cases reported herein, it was responsible for the decreased clearance of victim drugs even before addition of the perpetrator, so that the toxic range was more easily reached in DDI conditions. Interestingly, the steady-state plasma levels of sorafenib, a CYP3A substrate whose liver metabolism is minor (\ 30%) [186] , were increased threefold 2 weeks after the introduction of felodipine, another substrate of CYP3A, in a patient with hepatocellular carcinoma. While ketoconazole did not increase the AUC of single-dose sorafenib in healthy volunteers [187] , the introduction of the CYP3A substrate felodipine resulted in a clinically significant increase in sorafenib steady-state levels. The explanation for such significant DDIs may involve other routes of elimination (sorafenib is also a substrate of UDP-glucuronyltransferases [48]), as well as alteration of sorafenib metabolism due to hepatocellular carcinoma and cirrhosis. Indeed in vitro maximal velocities of sorafenib oxidation and glucuronidation were reduced by 25-and 2-fold, respectively, in tumor liver microsomes compared with control hepatic microsomes [188] . Moreover, among hepatocellular carcinoma patients, those with Child-Pugh B cirrhosis showed 20% higher sorafenib exposure compared with Child-Pugh A cirrhosis [98] .
To summarize, cirrhosis is associated with decreased CYP expression, liver blood flow, and hepatic uptake, which lead to alteration of drug hepatic clearance. It might also affect renal function through hepatorenal syndrome. This might result in the achievement of toxic levels of drugs, potentially leading to clinically relevant consequences. Regarding the magnitude of DDIs, current knowledge indicates that the impact of CYP inhibitors might be reduced by liver dysfunction. Therefore, while the addition of a CYP inhibitor might require dose adaptation in the presence of a CYP inhibitor in healthy volunteers, it might not be the case for advanced cirrhotic patients. Static [189] and dynamic models [179, 190] have been proposed to predict the exposure of drugs in cirrhotic patients based on the Child-Pugh classification. When incorporating cirrhosis-related physiological changes into the semi-mechanistic PBPK models, predicted drug concentrations corroborated with observed data [179, 190] . However, recent work indicates underprediction of lopinavir exposure changes in cirrhotic patients by PBPK modeling, which highlights the need to provide additional efforts to address knowledge gaps in virtual hepatic impairment populations before being able to predict complex DDIs involving liver diseases with PBPK modeling [191] .
Inflammation
Systemic inflammation markers have been identified in a number of diseases, such as advanced cancer, inflammatory diseases (rheumatoid arthritis, psoriasis), and infection (influenza infection, sepsis) [192] . In addition, inflammation is the result of oncologic treatment by recently marketed immunotherapy agents [193, 194] . With the recent development of such immunotherapies, closer scientific attention has been brought to the reduction of CYP-mediated drug metabolism and transport in inflammatory conditions [194] .
The underlying mechanisms of reduced CYP activity and expression have been investigated in vitro [195] [196] [197] [198] [199] [200] and are not only related to transcriptional suppression but also in part to post-translational protein modification caused by proinflammatory cytokines, with the most potent being IL-6, tumor necrosis factor (TNF)-a, IL-1b, and interferon (IFN)-c [201] . In rheumatoid arthritis patients, tocilizumab, a humanized, monoclonal, antihuman IL-6 receptor (IL-6R) antibody, reversed IL-6-induced suppression of CYP3A4 activity, as demonstrated by a decrease of simvastatin exposure of approximately 60 and 38% 1 and 5 weeks after tocilizumab infusion, respectively [202] . Similarly, sarilumab, a human monoclonal antibody blocking IL-6R, also provoked a decrease in simvastatin exposure of approximately 50% 7 days after a single-dose administration [203] . Using a cocktail approach, the activity of CYP3A (probe midazolam), CYP2C19 (probe omeprazole), and CYP2C9 (probe warfarin) was increased after sirukumab administration in rheumatoid arthritis patients [204] . Consequently, PBPK models were developed in order to predict the impact of elevated IL-6 levels on CYP3A4 and the treatment effect of tocilizumab and sirukumab in rheumatoid arthritis patients [205, 206] . Moreover, cancer immunotherapy agents have also been associated with IL-6-mediated CYP suppression. [193] While the impact of IL-6 as a marker of systemic inflammation on CYP3A repression now appears to be clear, additional knowledge is required in order to assess the impact of disease-related inflammatory response on drug exposure.
The effect of inflammation on DDIs has only been investigated in relation to CYP induction, and it was evidenced in human hepatocytes that proinflammatory cytokines such as IL-6 or TNFa inhibit the b-naphthoflavone-mediated induction of CYP1A enzymes and the rifampin-mediated induction of CYP3A [207] . The inducibility of CYP2B6 and CYP2C was also decreased by IL-6, probably through negative regulation of the nuclear constitutive androstane receptor (CAR) and the pregnane X receptor (PXR) gene expression [208] .
In the present case reports review, only three cases of DDIs in inflammatory status patients were retained from the literature search, mainly because inflammatory markers such as CRP, IL-6, or white blood cell count were rarely reported in reviewed publications. As reported in advanced cancer patients, CRP, IL-6, a1-acid glycoprotein, and TNFa seem to be the inflammatory markers that have the greatest correlation between inflammatory response and decreased CYP-mediated drug clearance [192] .
In two of these cases, inflammation was a compounding factor of DDI-related ADRs, in addition to renal impairment, cirrhosis, or genetic polymorphisms. As an example, severe extrapyramidal symptoms were related to haloperidol toxicity when comedicated with the moderate CYP3A inhibitor ciprofloxacin in a patient, combining four compounding factors: CYP2D6*6/*6 (PM) and UGT2B7 -161 CT (IM) genotypes, cirrhosis, and acute inflammation as reported by high CRP levels [61] .
Although significant advances have been proposed in the field of inflammation-induced CYP repression, clinical evidence is still scarce and is mostly limited to the impact of IL-6 on CYP3A activity. Further research is needed in order to investigate the impact of both chronic and acute inflammation on other CYPs and transporters. Nonetheless, available population PK (PopPK) and PBPK models have shown their ability to simulate interactions between inflammatory diseases and the PK of CYP substrates, which paves the way for model-informed drug exposure predictions and dose-finding strategies. As with the other diseases described in the present review, PBPK might represent a useful tool in order to predict complex scenarios of DDIs in the context of systemic inflammation, provided that the PK changes related to inflammatory status that are fed into the model are validated. Moreover, the impact of surrogate markers of systemic inflammation other than IL-6 on CYP activity and/or expression, as well as their combination, remains to be investigated.
Clinical Perspectives
Computerized physician order entry (CPOE) systems currently include DDI checking tools, most of which are integrating alert systems [209] . In some advanced systems, renal and hepatic functions can also be incorporated, and dose adaptation might be recommended according to the estimated GFR and/or liver functional status [210] . A recent meta-analysis highlighted the discrepancy between the high prevalence of potential DDIs and the low prevalence of actual DDIs leading to clinical harm [211] . DDI checking tools included in CPOE systems only have poor positive predictability and may cause annoyance and frustration through overexposure to prescription alerts [212] , especially when prescription assistance is lacking.
While therapeutic drug monitoring might represent the gold standard for assessing drug exposure, the approach is not feasible for all drugs and patients, it is resource-consuming, and it cannot predict exposure prior to the actual drug dosing. Phenotyping of drug-metabolizing enzymes has the major advantage of taking into account both intrinsic and extrinsic factors influencing enzyme activity and expression, and is currently often used in Geneva University Hospitals in order to support the management of complex drug interaction scenarios [213] . However, this approach is not yet performed routinely and requires time for analysis and administration of xenobiotics, even at low doses. The management of complex drug interaction scenarios involving intrinsic (genetic polymorphisms and/or diseases affecting drug disposition) and extrinsic (concomitant medications) factors is thus challenging and relies on several prerequisites.
First, the prescriber needs to be aware of concomitant medications, diseases, or medical conditions that may affect the PK of the prescribed treatment. Therefore, preand post-graduate education of physicians to PK, pharmacogenetics, and DDIs is highly recommended to ensure that prescribers are aware of intrinsic and extrinsic factors leading to drug safety and efficacy issues. In addition, the use of advanced CPOE systems that integrate a DDI checking tool, laboratory data (genetic results, liver function tests, creatinine clearance/GFR, biomarkers of systemic inflammation), and clinical information (known allergies, pregnancy, weight, sex) may represent a great asset to gather all relevant data needed to optimize drug prescription.
Moreover, the main issue remains the ability to accurately predict the clinical outcome of such complex drug interactions. In clinical practice, the prescriber may not have sufficient PK knowledge and confidence to adjust drug dosage based on the patients' characteristics, and may refer to a clinical pharmacology consultancy. Although pharmacogenetics is expanding in clinical practice, the prescriber is often confused when interpreting a pharmacogenetic result. A US survey reported that 98% of physicians agree that genetics may predict drug response; however, only 10% feel adequately informed to actually use genetic tests [214] . Therefore, providing more focus on pharmacogenetics, which is expected to grow bigger and bigger in future years with the paradigm shifting from universal to personalized medicine, in the education of healthcare professionals, seems necessary. Pharmacogenetic education to physicians allowed the successful adoption of healthcare models of pre-emptive pharmacogenetic testing [215] . In addition, the clinical validation of pharmacogenetic markers is an important prerequisite for further implementation. Pharmacogenomics data may not be sufficient to reliably predict a clinical response to a drug, particularly when the impact of genetic variants on the PD outcome is moderate [216] or when the relation with clinical outcome is affected by other patients' characteristics or clinical settings [217] .
Current knowledge does not yet allow for the management of complex drug interactions, even though static mechanistic models and dynamic PBPK models have been developed to address this issue. While a static prediction tool might present the advantage of simplicity and applicability in a clinical setting, PBPK modeling seems more able to handle such complex scenarios, as demonstrated with DDIs involving genetic polymorphisms or race-related changes in CYP abundance [156, 218] . In the past years, model-informed approaches have been successively used to optimize drug dosing in special populations and appear to be efficient tools for improving the efficacy and safety of a drug treatment for an individual patient by integrating its own characteristics in the model [219] . While a few issues currently hamper their widespread use in clinical practice, including limited evidence of efficacy, weak awareness of the approach in the clinical community, and lack of cost-benefit analysis, we think that future implementation of such comprehensive tools may help to manage complex clinical scenarios in relation to drug dosing (see Fig. 2 ). The development of international guidelines for the management of complex drug interactions is however a prerequisite for further clinical implementation.
Conclusions
More than 60 case reports of complex DDIs were identified from our systematic literature search. The analysis of these reports on DDIs involving intrinsic factors such as genetic polymorphisms or diseases showed their association with drug exposure. Although the additive role of intrinsic factors in the clinical relevance of DDIs is not clearly demonstrated in some case reports presented in this systematic review, there is evidence suggesting that both intrinsic and/or extrinsic factors have an impact on the extent of DDIs and the severity of clinical outcomes. Indisputably, the presented case reports are real-life illustrations of the issue of complex DDIs in clinical practice. Further research and dedicated clinical trials are needed to appraise the clinical relevance of complex drug interactions involving extrinsic and intrinsic factors. Current data indicate a greater variability in drug levels and exposure when such complex DDIs are present, compared with simple DDIs. This variability results in poor predictability of the DDIs and to the potentially dramatic clinical consequences that were described in the present review. In clinical practice, the management of such complex scenarios of DDIs is currently empiric due to the lack of prediction tools. The future development of such tools available for clinical practice, including PBPK modelbased precision dosing tools, is expected to bring more confidence in the management of complex scenarios and therefore to decreasing the rate of DDI-related adverse reactions.
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